步长制药：控股子公司获得四价流感病毒裂解疫苗药品注册证书

Core Viewpoint - The company has received approval from the National Medical Products Administration for its quadrivalent influenza virus split vaccine, which is intended to stimulate the immune response against influenza viruses [1] Group 1 - The vaccine is primarily used to prevent influenza caused by the relevant strains of the virus [1] - The company has invested approximately 126 million yuan in research and development for the quadrivalent influenza virus split vaccine project as of June 30, 2025 [1]